Table 1 Demographic characteristics of the patients used and non-used N-acetylcysteine in Taiwan
Variable | N-acetylcysteine useda | Standardized mean differenceb | |
|---|---|---|---|
No | Yes | ||
n = 51,715 | n = 12,928 | ||
N (%) | N (%) | ||
Sex | |||
Female | 23,379 (45.2) | 5838 (45.2) | 0.001 |
Male | 28,336 (54.8) | 7090 (54.8) | 0.001 |
Age at baseline, years | |||
25–39 years | 1718 (3.3) | 485 (3.8) | 0.023 |
40–64 years | 34,088 (65.9) | 8578 (66.4) | 0.009 |
Older than 65 years | 15,909 (30.8) | 3865 (29.9) | 0.019 |
Mean (SMD) | |||
Comorbidities | |||
Myocardial infarction | 776 (1.5) | 239 (1.9) | 0.027 |
Congestive heart failure | 2109 (4.1) | 665 (5.1) | 0.051 |
Cerebral vascular disease | 6447 (12.5) | 1739 (13.5) | 0.029 |
Rheumatoid arthritis | 790 (1.5) | 201 (1.6) | 0.002 |
Systemic lupus erythematosus | 267 (0.5) | 73 (0.6) | 0.007 |
Diabetes mellitus | 10,997 (21.3) | 2805 (21.7) | 0.011 |
Hypertension | 23,911 (46.2) | 5850 (45.3) | 0.020 |
Gout | 7109 (13.8) | 1832 (14.2) | 0.012 |
Septic arthritis | 156 (0.3) | 50 (0.4) | 0.015 |
Aseptic necrosis | 234 (0.5) | 57 (0.4) | 0.002 |
COPD | 13,814 (26.7) | 3647 (28.2) | 0.034 |
Obesity | 463 (0.9) | 116 (0.9) | < 0.001 |
Osteoarthritis of hand | 36 (0.1) | 9 (0.1) | < 0.001 |
Previous knee, leg, ankle, and foot injury | 113 (0.2) | 21 (0.2) | 0.013 |